TABLE 2.
Stage‐specific lung cancer cases in three cancer registries a in Japan, 1993 to 2015, by period of diagnosis and histological type
| Characteristic | Male | Female | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall, N = 44 113 b | 1993‐1999, N = 10 807 b | 2000‐2004, N = 9215 b | 2005‐2009, N = 10 559 b | 2010‐2015, N = 13 532 b | P‐value c | Overall, N = 18 757 b | 1993‐1999, N = 4141 b | 2000‐2004, N = 3834 b | 2005‐2009, N = 4498 b | 2010‐2015, N = 6284 b | P‐value c | |
| Small cell carcinoma | 4593 (100.0%) | 1206 (100.0%) | 988 (100.0%) | 1060 (100.0%) | 1339 (100.0%) | <.001 | 822 (100.0%) | 214 (100.0%) | 165 (100.0%) | 201 (100.0%) | 242 (100.0%) | <.001 |
| Localized | 326 (7.1%) | 81 (6.7%) | 76 (7.7%) | 70 (6.6%) | 99 (7.4%) | 53 (6.4%) | 18 (8.4%) | 7 (4.2%) | 13 (6.5%) | 15 (6.2%) | ||
| Regional | 1284 (28.0%) | 355 (29.4%) | 259 (26.2%) | 333 (31.4%) | 337 (25.2%) | 229 (27.9%) | 67 (31.3%) | 48 (29.1%) | 56 (27.9%) | 58 (24.0%) | ||
| Distant | 2247 (48.9%) | 514 (42.6%) | 409 (41.4%) | 508 (47.9%) | 816 (60.9%) | 390 (47.4%) | 74 (34.6%) | 58 (35.2%) | 104 (51.7%) | 154 (63.6%) | ||
| Unknown/missing | 736 (16.0%) | 256 (21.2%) | 244 (24.7%) | 149 (14.1%) | 87 (6.5%) | 150 (18.2%) | 55 (25.7%) | 52 (31.5%) | 28 (13.9%) | 15 (6.2%) | ||
| Squamous cell carcinoma | 10 950 (100.0%) | 3001 (100.0%) | 2273 (100.0%) | 2536 (100.0%) | 3140 (100.0%) | <.001 | 1223 (100.0%) | 318 (100.0%) | 250 (100.0%) | 271 (100.0%) | 384 (100.0%) | <.001 |
| Localized | 2826 (25.8%) | 720 (24.0%) | 523 (23.0%) | 640 (25.2%) | 943 (30.0%) | 280 (22.9%) | 70 (22.0%) | 50 (20.0%) | 65 (24.0%) | 95 (24.7%) | ||
| Regional | 4081 (37.3%) | 1136 (37.9%) | 819 (36.0%) | 985 (38.8%) | 1141 (36.3%) | 399 (32.6%) | 95 (29.9%) | 78 (31.2%) | 94 (34.7%) | 132 (34.4%) | ||
| Distant | 2573 (23.5%) | 610 (20.3%) | 457 (20.1%) | 610 (24.1%) | 896 (28.5%) | 325 (26.6%) | 75 (23.6%) | 65 (26.0%) | 62 (22.9%) | 123 (32.0%) | ||
| Unknown/missing | 1470 (13.4%) | 535 (17.8%) | 474 (20.9%) | 301 (11.9%) | 160 (5.1%) | 219 (17.9%) | 78 (24.5%) | 57 (22.8%) | 50 (18.5%) | 34 (8.9%) | ||
| Adenocarcinoma | 15 344 (100.0%) | 3403 (100.0%) | 3103 (100.0%) | 3732 (100.0%) | 5106 (100.0%) | <.001 | 10 963 (100.0%) | 2243 (100.0%) | 2161 (100.0%) | 2645 (100.0%) | 3914 (100.0%) | <.001 |
| Localized | 4880 (31.8%) | 790 (23.2%) | 865 (27.9%) | 1201 (32.2%) | 2024 (39.6%) | 4886 (44.6%) | 758 (33.8%) | 854 (39.5%) | 1209 (45.7%) | 2065 (52.8%) | ||
| Regional | 3930 (25.6%) | 1027 (30.2%) | 857 (27.6%) | 1001 (26.8%) | 1045 (20.5%) | 2195 (20.0%) | 576 (25.7%) | 500 (23.1%) | 562 (21.2%) | 557 (14.2%) | ||
| Distant | 5006 (32.6%) | 1091 (32.1%) | 879 (28.3%) | 1207 (32.3%) | 1829 (35.8%) | 2918 (26.6%) | 605 (27.0%) | 526 (24.3%) | 650 (24.6%) | 1137 (29.0%) | ||
| Unknown/missing | 1528 (10.0%) | 495 (14.5%) | 502 (16.2%) | 323 (8.7%) | 208 (4.1%) | 964 (8.8%) | 304 (13.6%) | 281 (13.0%) | 224 (8.5%) | 155 (4.0%) | ||
| Other (LAC, NSMC and unspecified types) | 8588 (100.0%) | 2164 (100.0%) | 1825 (100.0%) | 2087 (100.0%) | 2512 (100.0%) | <.001 | 3465 (100.0%) | 842 (100.0%) | 741 (100.0%) | 803 (100.0%) | 1079 (100.0%) | <.001 |
| Localized | 1027 (12.0%) | 148 (6.8%) | 107 (5.9%) | 254 (12.2%) | 518 (20.6%) | 463 (13.4%) | 73 (8.7%) | 61 (8.2%) | 100 (12.5%) | 229 (21.2%) | ||
| Regional | 1462 (17.0%) | 321 (14.8%) | 269 (14.7%) | 395 (18.9%) | 477 (19.0%) | 390 (11.3%) | 95 (11.3%) | 72 (9.7%) | 100 (12.5%) | 123 (11.4%) | ||
| Distant | 2232 (26.0%) | 473 (21.9%) | 399 (21.9%) | 580 (27.8%) | 780 (31.1%) | 901 (26.0%) | 176 (20.9%) | 192 (25.9%) | 202 (25.2%) | 331 (30.7%) | ||
| Unknown/missing | 3867 (45.0%) | 1222 (56.5%) | 1050 (57.5%) | 858 (41.1%) | 737 (29.3%) | 1711 (49.4%) | 498 (59.1%) | 416 (56.1%) | 401 (49.9%) | 396 (36.7%) | ||
| Unknown/missing | 4638 (100.0%) | 1033 (100.0%) | 1026 (100.0%) | 1144 (100.0%) | 1435 (100.0%) | <.001 | 2284 (100.0%) | 524 (100.0%) | 517 (100.0%) | 578 (100.0%) | 665 (100.0%) | <.001 |
| Localized | 208 (4.5%) | 27 (2.6%) | 25 (2.4%) | 62 (5.4%) | 94 (6.6%) | 81 (3.5%) | 10 (1.9%) | 7 (1.4%) | 26 (4.5%) | 38 (5.7%) | ||
| Regional | 486 (10.5%) | 65 (6.3%) | 86 (8.4%) | 126 (11.0%) | 209 (14.6%) | 154 (6.7%) | 19 (3.6%) | 32 (6.2%) | 41 (7.1%) | 62 (9.3%) | ||
| Distant | 1256 (27.1%) | 176 (17.0%) | 215 (21.0%) | 346 (30.2%) | 519 (36.2%) | 532 (23.3%) | 87 (16.6%) | 104 (20.1%) | 131 (22.7%) | 210 (31.6%) | ||
| Unknown/missing | 2688 (58.0%) | 765 (74.1%) | 700 (68.2%) | 610 (53.3%) | 613 (42.7%) | 1517 (66.4%) | 408 (77.9%) | 374 (72.3%) | 380 (65.7%) | 355 (53.4%) | ||
a
The three Japanese cancer registries are in Yamagata, Fukui and Nagasaki prefectures.
b
Frequency (%).
c
Pearson's χ 2 test.